Previous 10 | Next 10 |
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not yet known what risks it poses to public health. G...
RedHill Biopharma (NASDAQ:RDHL) announced that the newly detected Omicron variant of the coronavirus is unlikely to impact its experimental COVID-19 therapies, Opaganib and RHB-107. Opaganib developed for hospitalized patients with the advanced form of the disease, targets the human host cell...
Adicet Bio (NASDAQ:ACET) +46% announces positive interim clinical data from first-ever allogeneic, off-the-shelf, Gamma Delta CAR T investigational cell therapy CF Acquisition (NASDAQ:CFVI) +26% Trump social media SPAC confirms $1B PIPE deal Digital Wor...
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants...
RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations Canada NewsWire Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore ...
RedHill Biopharma (NASDAQ:RDHL) announces the publication of a new study in the journal GastroHep, showing the high efficacy of Talicia in eradicating H. pylori irrespective of patient BMI and level of obesity in clinical trials. RDHL shares up 6.3% premarket at $2.89. This new...
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication treatment failure; Newly published data in GastroHep shows high eradication rates for Talicia ...
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI High Body Mass Index and obesity are known risk factors for H. Pylori eradication treatment failure; Newly published data in GastroHep shows high eradication rates for ...
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik® approved for inclusion as preferred and unrestricted brand on a major National Medicare Part D formulary serving more th...
RedHill Biopharma's Movantik ® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans Movantik ® approved for inclusion as preferred and unrestricted brand on a major National Medicare Part D formulary s...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...